Member Info for ant15

Turner Pope are a bucket shop the sooner APTA ditch them the better. As for trades today with the exception of the first two all have been buys. The update today was purely technical it was never intended to be a trading announcement that will follow shortly. I've mentioned Patience here several times before and it is all that is required now All the building blocks are in place. Just wait until the platform starts throwing up leads that APTA can convert to partnerships and potential royalty fees.

Ahead of an financial trading update in a couple of weeks time this is just what was needed. AI and robotics are essential tools for keeping pace with the outcomes demanded by clients who will ultimately pay for all the kit. As with all biotechs the devils in the detail and its always time. I cannot fault the management and look forward to reading the trading update very shortly. This is a quite exceptional company. ANT

Morning Freddie added a further 3,000,000 this am It is all looking good as I understand at the moment ant

I think this is a wise move The current political situation globally might well deteriorate and raising money for new products and research become strained. Its made a mess of my targets but only temporarily 2-3 months from now with news flow it will be forgotten but not the fact that they are expanding and have a cash run way to 2028. I do however echo thoughts about brokers as here TP who should have taken warrants with an exercise price at circa 1.9 p which would instil more confidence and not just greed.

You are right of course on the AGM 5% I had wrongly recalled a figure before the law changed and the ability to call one However I stand by the rest of my post . I think the directors should be writing to shareholders pointing out the very real prospects of a rerating of the shares when DoseMe gains traction You might not agree but it is the most sensible thing they should do, a letter all shareholders explaing just what the potential is. Peter Hoskins

This is a highly specialist company Unlike so many others they are heavily dependent on the expertise of all concerned and are now ( at long last ) beginning to show really positive signs that they can emerge as a force within the sector. I would like to see them rebrand as Physiomics AI Not because it is topical but because it is what they are doing and how they arrive at their results. Furthermore it will raise curiosity and understanding from others who may wish to invest in AI and there are a lot. I was extremely upset when we had dilution a year ago that witnessed all LTH's taking a bath ( excuse the expression ) As for buying I will sit and wait to see what transpires over the next few weeks and will then seek to add to my holding. My advice for what its worth I wouldn't trust the approach to wrench control which should be resisted at all costs. Peter Hoskins

This is a clever move unless I am wrong it dilutes 13% plus to 9.1% and will either spark buying to increase to 10% or result in a fresh application for an EGM summating two of the significant shareholdings to arrive at 10% . This is going to be a long drawn out process that has been played out before on AIM. These characters know nothing of the business and should not be even entertained. Peter Hoskins

REPEATED FROM EARLIER It would be an extremely foolish move to appoint t the individuals concerned. This is not a like for like change of control the incoming board know nothing of the very specialist nature of the business Anyone believing that this would or could be for the good of the company and its science has no idea . Vote to exclude the lot of them!

As an aside we all noticed how the company suffered without the expert knowledge of Christophe it has now been replaced with others Don't let it happen again. As Ever Peter Hoskins

It would be an extremely foolish move to appoint t the individuals concerned. This is not a like for like change of control the incoming board know nothing of the very specialist nature of the business Anyone believing that this would or could be for the good of the company and its science has no idea . Vote to exclude the lot of them!

As an aside we all noticed how the company suffered without the expert knowledge of Christophe it has now been replaced with others Don't let it happen again. As Ever Peter Hoskins

Morning Freddie, I picked up a few more this am 74,553 shows as a sell but not to worry. I try to get the odd buys each week now to add to the pot. I think we are about to really motor and day now.

Well done you beat me to it by a whisker Phase 2 one presumes will follow shortly.

Has anyone done the maths on 16,400 barrels a day? !!!!

The question is simple who is the whale and has "it" now accumulated a holding that will need to be disclosed to the market 3% If not continued buying if it has then an announcement will be forthcoming as it is formally required. Tomorrow and next week should be very interesting and potentially profitable trading days.

It would seem as though the 1,750,000 was a negotiated buy then?

Massively undervalued and it comes as no surprise that its attracting attention at long last.

On APTA the best is yet to come as with all biotech the time lines to success are so protracted. I am pleased to see that both are doing well. Thank you for the welcome Laura I read the posts but rarely post on here myself Still holding a large number. but more than certain that the turn around has begun. Ant

If its to be taken out it will be a far higher levels I am surprised that they haven't rebranded as they are most certainly the first AI company to have floated globally. The technology came straight out of artificial intelligence from the very start. Time for a re rate yes lets see about the rest!!!

It only gets better Ist royalty payments in and a new contract!

Freddie I can see Simon V's post and note that Neuro Bio have received significant funds to continue to develop a therapeutic for Alzheimer but whilst there are others engaged in this field non have developed an accurate saliva based test for early detection up to 20 years before significant onset. Neuro Bio and Aptamer have and are seeking to commercialise their discovery. You will recall that whilst others had proposed a blood based test for COVID detection the couldn't pass the final regulatory hurdles as being invasive This test is by far the best. The best thing to come out of the BBC report is that it highlights the need which will definitely benefit Neuro Bio and Aptamer. It would seem as though some shareholders are oblivious to the potential of APTA which this year will start to deliver on projects that are royalty revenue generating and highly profitable. As I always say its only a matter of patience.Ant

Not a penny but shorting might take it down to the 40p mark again before anyone tries to load up The stock is really being played and the lack of news doesn't help.

It has always been the case their share of the sector is worth over $30 billion. APTA are well positioned to play a strategic role that will be worth many millions in passive income annually Ask your self what will the share price be then and could it happen in the current year? YES.